Cartesian Therapeutics announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis. Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy product candidate targeting B-cell maturation antigen. Descartes-08 is designed to be administered without preconditioning chemotherapy and does not use integrating vectors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics announces employment inducement grant
- Cartesian Therapeutics Announces New Employment Inducement Grant
- Cartesian announces first patient dosed in Phase 1 trial of Descartes-15
- Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
- Cartesian Therapeutics price target lowered to $45 from $49 at H.C. Wainwright